FHTX Q3 2023 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+163.5% YoY

Gross Profit

-$9M-50.2% margin

Operating Income

-$17M-97.7% margin

Net Income

-$14M-82.1% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+212.2%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$313M

Total Liabilities

$371M

Stockholders' Equity

-$57M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$7M	+163.5%
Gross Profit	-$9M	-$20M	+56.8%
Operating Income	-$17M	-$28M	+39.6%
Net Income	-$14M	-$26M	+44.3%